Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entrada Therapeutics (TRDA) Current Assets (2022 - 2025)

Entrada Therapeutics (TRDA) has 4 years of Current Assets data on record, last reported at $306.3 million in Q4 2025.

  • For Q4 2025, Current Assets fell 30.4% year-over-year to $306.3 million; the TTM value through Dec 2025 reached $306.3 million, down 30.4%, while the annual FY2025 figure was $306.3 million, 30.4% down from the prior year.
  • Current Assets reached $306.3 million in Q4 2025 per TRDA's latest filing, down from $338.3 million in the prior quarter.
  • Across five years, Current Assets topped out at $489.5 million in Q2 2024 and bottomed at $209.9 million in Q4 2022.
  • Average Current Assets over 4 years is $360.9 million, with a median of $376.4 million recorded in 2023.
  • Peak YoY movement for Current Assets: surged 76.19% in 2023, then tumbled 30.4% in 2025.
  • A 4-year view of Current Assets shows it stood at $209.9 million in 2022, then soared by 76.19% to $369.8 million in 2023, then rose by 19.0% to $440.0 million in 2024, then crashed by 30.4% to $306.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Current Assets were $306.3 million in Q4 2025, $338.3 million in Q3 2025, and $369.1 million in Q2 2025.